STAT3 and neoplasm: After CAR-T cells target tumor antigens, the JAK and STAT3/5 signaling pathways are immediately triggered by IL-2R β fragments, thereby augmenting the antitumor efficacy and in vivo persistence of T cells (Kagoya et al., 2018; Tokarew et al., 2019).